Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance
- PMID: 16397273
- DOI: 10.1158/0008-5472.CAN-05-2776
Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance
Erratum in
- Cancer Res. 2006 Jun 1;66(11):5976
Abstract
We have previously shown that natural cytotoxic activity of peripheral blood lymphocytes was inversely related to cancer development based on a prospective cohort study. The genetic fraction of cytotoxic activity needs to be clarified, identifying individuals immunogenetically susceptible to cancer. A case-control study within the cohort members was designed: 102 cancer cases with peripheral lymphocyte DNA available and three control groups, each of which consisted of 204 subjects with each tertile level of cytotoxic activity. We first compared two control groups with high and low cytotoxic activity in terms of the single nucleotide polymorphisms in the natural killer complex gene region on chromosome 12p, identifying the haplotype alleles that were associated with the activity. Next, cancer risks were assessed for these haplotypes. We found two haplotype blocks, each of which generated two major haplotype alleles: low-activity-related LNK1 (frequency 0.478 and 0.615 in groups with high and low activity, respectively; P < 0.00008) and high-activity-related HNK1 (0.480 and 0.348; P < 0.0001), LNK2 (0.711 and 0.821; P < 0.0002), and HNK2 (0.272 and 0.174; P < 0.0008). These NKG2D haplotype alleles showed a significant difference between cases (0.632 for LNK1 and 0.333 for HNK1) and controls (0.554 for LNK1 and 0.406 for HNK1). The haplotype HNK1/HNK1 revealed a decreased risk of cancer (odds ratio, 0.471; 95% confidence interval, 0.233-0.952) compared with LNK1/LNK1. Individuals who are genetically predisposed to have low or high natural cytotoxic activity can in part be determined by NKG2D haplotyping, which in turn reveals an increased or decreased risk of cancer development.
Similar articles
-
Effects of NKG2D haplotypes on the cell-surface expression of NKG2D protein on natural killer and CD8 T cells of peripheral blood among atomic-bomb survivors.Hum Immunol. 2012 Jun;73(6):686-91. doi: 10.1016/j.humimm.2012.03.003. Epub 2012 Apr 13. Hum Immunol. 2012. PMID: 22507622
-
Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese.Carcinogenesis. 2008 Feb;29(2):316-20. doi: 10.1093/carcin/bgm260. Epub 2008 Jan 3. Carcinogenesis. 2008. PMID: 18174257
-
Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms.Hepatology. 2008 Jan;47(1):90-6. doi: 10.1002/hep.21964. Hepatology. 2008. PMID: 18023027
-
NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes.Semin Immunol. 2006 Jun;18(3):167-75. doi: 10.1016/j.smim.2006.03.001. Epub 2006 May 24. Semin Immunol. 2006. PMID: 16723257 Review.
-
The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.Clin Cancer Res. 2007 Dec 15;13(24):7228-31. doi: 10.1158/1078-0432.CCR-07-2150. Clin Cancer Res. 2007. PMID: 18094399 Review. No abstract available.
Cited by
-
Donor NKG2D rs1049174 polymorphism predicts hematopoietic recovery and event-free survival after single-unit cord blood transplantation in adults.Bone Marrow Transplant. 2024 Apr;59(4):566-568. doi: 10.1038/s41409-024-02217-2. Epub 2024 Jan 24. Bone Marrow Transplant. 2024. PMID: 38267584 No abstract available.
-
Natural killer cells in non-hematopoietic malignancies.Front Immunol. 2012 Dec 24;3:395. doi: 10.3389/fimmu.2012.00395. eCollection 2012. Front Immunol. 2012. PMID: 23269924 Free PMC article.
-
The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer.Biology (Basel). 2023 Aug 2;12(8):1079. doi: 10.3390/biology12081079. Biology (Basel). 2023. PMID: 37626965 Free PMC article. Review.
-
MICA and NKG2D: Is There an Impact on Kidney Transplant Outcome?Front Immunol. 2017 Feb 27;8:179. doi: 10.3389/fimmu.2017.00179. eCollection 2017. Front Immunol. 2017. PMID: 28289413 Free PMC article. Review.
-
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.Oncoimmunology. 2015 Nov 25;5(4):e1100788. doi: 10.1080/2162402X.2015.1100788. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141381 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical